- Home
- BXC vs CRVS Comparison
BXC vs CRVS Comparison
Compare BXC & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BXC | CRVS |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.3M | 546.7M |
| IPO Year | 2004 | 2016 |
Fundamental Metrics
Financial Performance| Metric | BXC | CRVS |
|---|---|---|
| Price | $75.66 | $6.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $88.67 | $13.75 |
| AVG Volume (30 Days) | 94.5K | ★ 1.7M |
| Earning Date | 02-17-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $2,948,840,000.00 | N/A |
| Revenue This Year | $0.63 | N/A |
| Revenue Next Year | $3.06 | N/A |
| P/E Ratio | $42.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $52.71 | $2.54 |
| 52 Week High | $114.19 | $9.60 |
Technical Indicators
Market Signals| Indicator | BXC | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 72.24 | 36.34 |
| Support Level | $60.76 | $6.45 |
| Resistance Level | $65.76 | $7.18 |
| Average True Range (ATR) | 3.03 | 0.45 |
| MACD | 1.27 | -0.07 |
| Stochastic Oscillator | 97.49 | 22.36 |
Price Performance
Historical ComparisonAbout BXC Bluelinx Holdings Inc.
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).